Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis

Digestive and Liver Disease

Volumn 46, Issue 7, 2014, Pages 632-638

  Basili, Stefania ^a   Raparelli, Valeria ^a   Napoleone, Laura ^a   Del Ben, Maria ^a   Merli, Manuela ^a   Riggio, Oliviero ^a   Nocella, Cristina ^a   Carnevale, Roberto ^a   Pignatelli, Pasquale ^a   Violi, Francesco ^a   Angelico, Francesco ^b   Amoroso, Daria ^b   Bartimoccia, Simona ^b   Lelio Burgio, Vito ^b   Calabrese, Cinzia ^b   Carboni, Alessia ^b   De Felice, Olivia ^b   DiSanto, Serena ^b   Giannelli, Valerio ^b   Lucidi, Cristina ^b   Nigro, Carmen ^b   Pignataro, Francesca Serena ^b   Proietti, Marco ^b   Russo, Roberta ^b   Talerico, Giovanni ^b   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Gastroenterology Unit ^*

Author keywords

Isoprostanes; Liver cirrhosis; NADPH oxidase; Oxidative stress; Polyunsaturated fatty acids

Indexed keywords

ISOPROSTANE DERIVATIVE; LINOLEIC ACID; LINOLENIC ACID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; CYBB PROTEIN, HUMAN; MEMBRANE PROTEIN; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PEPTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

AGED; ARTICLE; CHILD PUGH SCORE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERVENTION STUDY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC BALANCE; OXIDATIVE STRESS; PRIORITY JOURNAL; REGULATORY MECHANISM; THROMBOCYTE FUNCTION; URINE LEVEL; BLOOD; CELL CULTURE; ENZYMOLOGY; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THROMBOCYTE; URINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FEMALE; HUMANS; ISOPROSTANES; LIVER CIRRHOSIS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NADPH OXIDASE; OXIDATIVE STRESS; PEPTIDES; REACTIVE OXYGEN SPECIES; SEVERITY OF ILLNESS INDEX;

EID: 84903816499     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.02.021     Document Type: Article

References (43)

1. Pinzani M., Rombouts K. Liver fibrosis: from the bench to clinical targets. Digestive and Liver Disease 2004, 36:231-242.
2. Gressner O.A., Weiskirchen R., Gressner A.M. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. Journal of Cellular and Molecular Medicine 2007, 11:1031-1051.
3. Gardi C., Arezzini B., Monaco B., et al. F2-isoprostane receptors on hepatic stellate cells. Laboratory Investigation 2008, 88:124-131.
4. Comporti M., Arezzini B., Signorini C., et al. Oxidative stress, isoprostanes and hepatic fibrosis. Histology and Histopathology 2009, 24:893-900.
5. De Minicis S., Seki E., Paik Y.H., et al. Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis. Hepatology 2010, 52:1420-1430.
6. Morrow J.D., Hill K.E., Burk R.F., et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:9383-9387.
7. Pignatelli P., Carnevale R., Di Santo S., et al. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 31:423-434.
8. Violi F., Basili S., Nigro C., et al. Role of NADPH oxidase in atherosclerosis. Future Cardiology 2009, 5:83-92.
9. Seno T., Inoue N., Gao D., et al. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thrombosis Research 2001, 103:399-409.
10. Basili S., Raparelli V., Riggio O., et al. NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation. Liver International 2011, 31:1533-1540.
11. Morgan M.J., Liu Z.G. Reactive oxygen species in TNF alpha-induced signaling and cell death. Molecules and Cells 2010, 30:1-12.
12. Calder P.C. n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. American Journal of Clinical Nutrition 2006, 83(Suppl.):1505S-1519S.
13. El-Badry A.M., Graf R., Clavien P.A. Omega 3-Omega 6: What is right for the liver?. Journal of Hepatology 2007, 47:718-725.
14. Lee S., Gura K.M., Puder M. Omega-3 fatty acids and liver disease. Hepatology 2007, 45:841-845.
15. Araya J., Rodrigo R., Videla L.A., et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clinical Science (London) 2004, 106:635-643.
16. Sekiya M., Yahagi N., Matsuzaka T., et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003, 38:1529-1539.
17. Videla L.A., Rodrigo R., Araya J., et al. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radical Biology and Medicine 2004, 37:1499-1507.
18. Alwayn I.P., Andersson C., Zauscher B., et al. Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation 2005, 79:606-608.
19. Kurihara T., Adachi Y., Yamagata M., et al. Role of eicosapentaenoic acid in lipid metabolism in the liver, with special reference to experimental fatty liver. Clinical Therapeutics 1994, 16:830-837.
20. Capanni M., Calella F., Biagini M.R., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Alimentary Pharmacology and Therapeutics 2006, 23:1143-1151.
21. Shapiro H., Tehilla M., Attal-Singer J., et al. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clinical Nutrition 2011, 30:6-19.
22. Nobili V., Sanyal A.J. Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. Journal of Gastroenterology 2012, 47:29-36.
23. Cussons A.J., Watts G.F., Mori T.A., et al. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. Journal of Clinical Endocrinology and Metabolism 2009, 94:3842-3848.
24. Oya J., Nakagami T., Sasaki S., et al. Intake of n-3 polyunsaturated fatty acids and non-alcoholic fatty liver disease: a cross-sectional study in Japanese men and women. European Journal of Clinical Nutrition 2010, 64:1179-1185.
25. Tanaka N., Sano K., Horiuchi A., et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. Journal of Clinical Gastroenterology 2008, 42:413-418.
26. Vega G.L., Chandalia M., Szczepaniak L.S., et al. Effects of N-3 fatty acids on hepatic triglyceride content in humans. Journal of Investigative Medicine 2008, 56:780-785.
27. Zhu F.S., Liu S., Chen X.M., et al. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World Journal of Gastroenterology 2008, 14:6395-6400.
28. Pignatelli P., Carnevale R., Cangemi R., et al. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 30:360-367.
29. Pugh R.N., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophagus for bleeding oesophageal varices. British Journal of Surgery 1973, 60:646-649.
30. Alessandri C., Pignatelli P., Loffredo L., et al. Alpha-linolenic acid-rich wheat germ oil decreases oxidative stress and CD40 ligand in patients with mild hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2006, 26:2577-2578.
31. Hoffman S.W., Roof R.L., Stein D.G. A reliable and sensitive enzyme immunoassay method for measuring 8-isoprostaglandin F2 alpha: a marker for lipid peroxidation after experimental brain injury. Journal of Neuroscience Methods 1996, 68:133-136.
32. Basili S., Pignatelli P., Tanzilli G., et al. Anoxia-reoxygenation enhances platelet thromboxane A2 production via reactive oxygen species-generated NOX2: effect in patients undergoing elective percutaneous coronary intervention. Arteriosclerosis, Thrombosis, and Vascular Biology 2011, 31:1766-1771.
33. Phang M., Lincz L., Seldon M., et al. Acute supplementation with eicosapentaenoic acid reduces platelet microparticle activity in healthy subjects. Journal of Nutritional Biochemistry 2012, 23:1128-1133.
34. Phang M., Sinclair A.J., Lincz L.F., et al. Gender-specific inhibition of platelet aggregation following omega-3 fatty acid supplementation. Nutrition, Metabolism and Cardiovascular Diseases 2012, 22:109-114.
35. Pratico D., Iuliano L., Basili S., et al. Enhanced lipid peroxidation in hepatic cirrhosis. Journal of Investigative Medicine 1998, 46:51-57.
36. Carnevale R., Iuliano L., Nocella C., et al. Relationship between platelet and urinary 8-Iso-PGF2α levels in subjects with different degrees of NOX2 regulation. Journal of the American Heart Association 2013, 2:e000198. 10.1161/JAHA.113.000198.
37. Watanabe A., Saito S., Tsuchida T., et al. Low plasma levels of docosahexaenoic acid in patients with liver cirrhosis and its correction with a polyunsaturated fatty acid-enriched soft oil capsule. Nutrition 1999, 15:284-288.
38. Cabré E., Periago J.L., Abad-Lacruz A., et al. Plasma fatty acid profile in advanced cirrhosis: unsaturation deficit of lipid fractions. American Journal of Gastroenterology 1990, 85:1597-1604.
39. González J., Periago J.L., Gil A., et al. Malnutrition-related polyunsaturated fatty acid changes in plasma lipid fractions of cirrhotic patients. Metabolism: Clinical and Experimental 1992, 41:954-960.
40. Johnson S.B., Gordon E., McClain C., et al. Abnormal polyunsaturated fatty acid patterns of serum lipids in alcoholism and cirrhosis: arachidonic acid deficiency in cirrhosis. Proceedings of the National Academy of Sciences of the United States of America 1985, 82:1815-1818.
41. Schmöcker C., Weylandt K.H., Kahlke L., et al. Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Hepatology 2007, 45:864-869.
42. Gura K.M., Duggan C.P., Collier S.B., et al. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics 2006, 118:e197-e201.
43. Ishii H., Horie Y., Ohshima S., et al. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. Journal of Hepatology 2009, 50:562-571.